利妥昔单抗治疗后，CD19是一种有用的B细胞标志物：对琼斯等人文章的评论 - Suppr

CD19 is a useful B cell marker after treatment with rituximab: comment on the article by Jones et al.

作者信息

Kamburova Elena G, Koenen Hans J M P, Joosten Irma, Hilbrands Luuk B

出版信息

Arthritis Rheum. 2013 Apr;65(4):1130-1. doi: 10.1002/art.37871.

DOI:10.1002/art.37871

PMID:23335076

Abstract

摘要

相似文献

CD19 is a useful B cell marker after treatment with rituximab: comment on the article by Jones et al.

Arthritis Rheum. 2013 Apr;65(4):1130-1. doi: 10.1002/art.37871.

B cells identified according to their expression of CD19 and surface Ig are depleted from peripheral blood by rituximab in patients with rheumatoid arthritis: comment on the article by Jones et al.

Arthritis Rheum. 2013 Apr;65(4):1132. doi: 10.1002/art.37869.

Reply: To PMID 22674374.

Arthritis Rheum. 2013 Apr;65(4):1132-3. doi: 10.1002/art.37870.

Rituximab mediates loss of CD19 on B cells in the absence of cell death.

Arthritis Rheum. 2012 Oct;64(10):3111-8. doi: 10.1002/art.34560.

CD22 is not expressed merely on B cells: comment on the article by Vos et al.

Arthritis Rheum. 2008 Mar;58(3):911-2; author reply 912-3. doi: 10.1002/art.23282.

Re-treatment of rheumatoid arthritis patients who were initial nonresponders to rituximab: comment on the article by Thurlings et al.

Arthritis Rheum. 2009 Jun;60(6):1867; author reply 1867-8. doi: 10.1002/art.24558.

CD19 mRNA quantification improves rituximab treatment-to-target approach: a proof of concept study.

J Neuroimmunol. 2014 Dec 15;277(1-2):127-33. doi: 10.1016/j.jneuroim.2014.09.008. Epub 2014 Sep 20.

Efficacy of rituximab in a patient with lupus nephritis despite low levels of CD19.

Rheumatology (Oxford). 2010 Dec;49(12):2452-3. doi: 10.1093/rheumatology/keq186. Epub 2010 Jun 29.

Successful treatment and clearing of circulating CD19-positive cells by rituximab in a child with idiopathic membranous nephropathy.

Pediatr Nephrol. 2011 Apr;26(4):637-8. doi: 10.1007/s00467-010-1671-2. Epub 2010 Oct 29.

CD20 epitope masking by rituximab: comment on the article by Gunnarsson et al.

Arthritis Rheum. 2008 Feb;58(2):634; author reply 634. doi: 10.1002/art.23298.

引用本文的文献

Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.

Front Immunol. 2021 Jan 11;11:609941. doi: 10.3389/fimmu.2020.609941. eCollection 2020.

Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.

Medicine (Baltimore). 2018 Nov;97(46):e13157. doi: 10.1097/MD.0000000000013157.

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Ann Oncol. 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056.

Extra-central nervous system target for assessment and treatment in refractory anti-N-methyl-d-aspartate receptor encephalitis.

J Crit Care. 2017 Feb;37:234-236. doi: 10.1016/j.jcrc.2016.09.016. Epub 2016 Sep 22.

Refractory Autoimmune Hepatitis: Beyond Standard Therapy.

Dig Dis Sci. 2016 Jun;61(6):1757-62. doi: 10.1007/s10620-015-4022-0. Epub 2016 Jan 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

CD19 is a useful B cell marker after treatment with rituximab: comment on the article by Jones et al.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献